Introduction {#S1}
============

To date, most gene therapy clinical trials have utilized viral vectors, but multiple concerns remain, including risks of carcinogenesis ^[@R1]^, acute immunogenicity ^[@R2]^, broad tropism ^[@R3]^, limited capacity for packaging of DNA ^[@R4]^, and challenges of safe handling and mass production ^[@R5]^. Alternative approaches to DNA delivery that improve upon these shortcomings are paramount to the translation of gene therapy to the clinic.

Cationic polymers such as polyethyleneimine (PEI) have been examined as synthetic gene carriers, taking advantage of their ability to complex with and condense nucleic acids into particles that readily enter cells, leading to efficient transfection. A critical challenge in their use is that the resulting positively charged gene/polymer complexes are prone to opsonization and uptake by the reticuloendothelial system (RES). As a result, circulating cationic particles may accumulate in the liver and spleen and fail to reach distant organs in sufficient quantities for therapeutic benefit. Modifying the surface of gene carriers with non-ionic hydrophilic polymers such as polyethylene glycol ("PEGylation") can reduce non-specific protein binding and uptake from circulation. However, PEGylation may similarly prevent transfection and thereby fail to induce therapeutic gene expression in target cells ^[@R6]^.

As an alternative to PEG, we and several other groups have used anionic polysaccharides such as hyaluronic acid ^[@R7]--[@R14]^ or dermatan sulfate (DS) ^[@R15],\ [@R16]^ to shield the cationic surface charge of gene-polymer complexes. An advantage of these polymers is that while they neutralize cationic charge, they do not compromise interaction with target cells. However, ternary polyplexes remain insufficiently stable in physiological fluid containing nucleases and anionic proteins to an extent that systemic application remained impractical ^[@R17]^. To overcome this challenge, cholesterol ^[@R18]--[@R21]^, aliphatic lipids ^[@R22]--[@R26]^, and deoxycholic acid ^[@R27]^ have been introduced as a lipid component to modify the cationic polymer to enhance hydrophobic interactions, leading to increased stability and enhanced transfection efficiency.

In this study, we modified low molecular weight linear PEI (LPEI, 2.5 kDa) with lithocholic acid (LCA). We chose LCA because of the hydrophobicity that enables self-assembly of the conjugate and its potential anti-cancer effect ^[@R28],\ [@R29]^. We tested gene transfection efficiency of LCA-conjugated LPEI complexed with DS as gene complexes in media similar to blood. In addition, we examined these polyplex nucleic acid carriers *in vivo* in tumor-bearing mice and found that they exhibited increased tumor accumulation as well as decreased off-target tissue accumulation relative to commercially available PEI and liposomal nucleic acid carriers.

We recently demonstrated that moderate doses of X-irradiation can be used to aid in the targeted delivery of liposomal chemotherapy, as well as other nanoparticle imaging agents, by affecting favorable modifications to the tumor microenvironment ^[@R30]^. Image-guided radiation enhanced the accumulation of all plasmid DNA conjugates to tumors, taking full advantage of the favorable properties of the LCA-conjugated LPEI complexed with DS as a carrier. Through designing an improved nucleic acid carrier in conjunction with exhibiting the utility of radiation-enhanced delivery, this study represents an important step towards making gene therapy clinically relevant.

Materials and Methods {#S2}
=====================

Study design {#S3}
------------

Minimum sample size was calculated a priori using a power value of 0.80. In cases where large numbers of animals would be required to obtain significance, the best judgment of the researchers regarding adequate sample size was used. Identification of outliers was performed using the ROUT method in Prism software. Data collection was discontinued when any dimension of a tumor reached 1--2 cm, as stated in the University of Chicago IACUC approved ACUP\# 72354.

This research was undertaken to assess what effect varying doses of X-irradiation have on targeting the delivery of various systemically administered plasmid DNA (pDNA) carriers to tumors over time using mice to model human cancer. For imaging studies, irradiation was performed when tumors reached a volume of 200--300 mm^3^. Animals were then assigned to treatment groups so that the mean tumor volume for each group was roughly equal. The mice were treated with X-irradiation, injected with varying pDNA-carrier complexes 3 days later, and examined using IVIS intravital imaging as detailed below. Cages contained mice from multiple treatment groups and researchers did not sort animals by treatment group when collecting data.

Synthesis of polyplex DNA carriers {#S4}
----------------------------------

LCA-LPEI conjugate ([3]{.ul} molar [e]{.ul}quivalent LCA to 1 mole LPEI, or 3E) was synthesized using carbodiimide chemistry. Forty micromolar LPEI (base form, Polysciences) and 120 μmol LCA were dissolved in 25 mL of dichloromethane (DCM). Dicyclohexyl carbodiimide (DCC) 120 μmol and N,N-diisopropyl-ethylamine (DIPEA) 120 μL were added to the mixture and reacted over 15 h. 3E was purified by dialysis against 95% ethanol followed by dialysis against acidified DI water. The resulting product was dissolved in D~2~O and analyzed with a Bruker ARX-300 NMR spectrometer equipped with a 5 mm QNP probe.

Preparation of binary and ternary polyplexes {#S5}
--------------------------------------------

Binary polyplexes were prepared by mixing polymer (LPEI or 3E) and pDNA at a specified ratio (0.1/1 to 3/1) and incubating in HEPES-buffered saline for 30 min at room temperature. For preparation of ternary polyplexes, the binary polyplexes were incubated with DS at a specified ratio (polymer/DS of 10/1 to 20/1) for 10 min at room temperature. The particle size and zeta potential of binary and ternary complexes were measured with a Zetasizer Nano-ZS90 (Malvern Instruments, Westborough, MA, U.S.A.). As-prepared samples were used for the size measurement. For zeta potential, the complexes were diluted in phosphate buffer (pH 7.4, 10 mM) to a concentration equivalent to 5 μg/mL of pDNA.

Gel retardation assay {#S6}
---------------------

DNA-binding capability of 3E was evaluated with the agarose gel retardation assay and compared with that of the starting material, LPEI. Binary polyplexes were prepared at a weight ratio of polymer/pDNA ranging from 0.1/1 to 3/1. The polyplexes (equivalent to 0.2 μg pDNA) were loaded in 1% agarose gel in 0.5× TAE buffer and run at 120 V for 25 min. The gel was stained with ethidium bromide, and DNA bands were detected at 302 nm using Azure C300 (Dublin, CA, U.S.A.). This experiment was repeated four times to ensure reproducibility.

*In vitro* stability assay {#S7}
--------------------------

To predict the stability of ternary polyplexes under mock physiological conditions, the complexes were treated with DNase and/or heparin and analyzed using gel electrophoresis. Each ternary complex was treated with 166 U/mL of DNase for 15 min and/or 4 mg/mL of heparin for 2 h and analyzed by gel electrophoresis in the same way as in the above gel retardation assay. This experiment was repeated four times to ensure reproducibility.

Cell culture {#S8}
------------

The cell lines used in this study were NIH3T3 mouse embryonic fibroblasts (ATCC, Manassas, VA, U.S.A.), MCF7 human mammary adenocarcinoma cells (ATCC), and TUBO murine mammary carcinoma cells (derived from BALB-neuT transgenic mice). NIH3T3 cells were cultured in DMEM supplemented with 10% fetal calf serum, 100 U/mL penicillin, and 100 μg/mL streptomycin. MCF7 cells were cultured in RPMI 1640 growth medium supplemented with 10% fetal bovine serum, 100 U/mL penicillin, and 100 μg/mL streptomycin. TUBO cells were cultured in RPMI 1640 growth medium supplemented with 1 U/mL penicillin and 1 μg/mL streptomycin, then resuspended in sterile 1× DPBS at a concentration of 1 × 10^7^ cells/mL for injection of 100 μL/mouse. All cell lines used in this study were tested for mycoplasma contamination.

Cytotoxicity assay {#S9}
------------------

Cells were seeded in 96 well plates at an initial density of 8 × 10^3^ (NIH3T3) or 1 × 10^4^ (MCF7) cells per well and incubated overnight. The medium was replaced with fresh medium containing LPEI or 3E at a concentration ranging from 0.8--50 μg/mL. After 48 h, cell viability was evaluated by measuring metabolic activity using the (3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyl-tetrazolium bromide) (MTT) assay. The MTT reagent and stop/solubilization solution were sequentially added with a 3 h interval. The formazan concentration was measured at 570 nm with a reference wavelength of 630 nm using a SpectraMax M3 microplate reader (Molecular Devices, Sunnyvale, CA, U.S.A.). The measured absorbance was normalized to the absorbance of control cells receiving no treatment. Each group was comprised of triplicate cultures with the experiment being repeated once to confirm reproducibility.

*In vitro* transfection efficiency assay {#S10}
----------------------------------------

NIH3T3 cells and MCF7 cells were seeded in a 24-well plate at a density of 2 × 10^4^ and 8 × 10^4^ cells per well, respectively. After 2 days, cells in each well were treated with polyplexes consisting of pEGFP-C1 plasmid (0.2 μg), polymers (2 or 4 μg) ± dermatan sulfate (DS, 0.2 μg) and incubated for 48 h (NIH3T3 cells) or 6 h followed by incubation in treatment-free medium for 42 h (MCF7 cells). GFP expression was visualized with a Cytation 3 imaging system (Biotek, Winooski, VT, U.S.A.) and quantified by measuring the fluorescence intensity of the cell lysate supernatant with a SpectraMax M3 microplate reader. Each group was comprised of triplicate cultures with the experiment being performed three times in total to confirm reproducibility.

Preparation of iRFP expression plasmid {#S11}
--------------------------------------

To generate an expression plasmid for optimal *in vivo* imaging in mice, a modified variant of the *Rhodopseudomonas palustris* bacteriophytochrome *Rp*BphP2, called iRFP for infraRed Fluorescent Protein (excitation/emission maxima at 690/713 nm) ^[@R31]^, was cloned from the pShuttle-CMV-iRFP plasmid (\#31856, Addgene, Cambridge, MA, U.S.A.). A BglII/NotI restriction double digest was used to insert the *iRFP* gene into the pEGFP-N1 plasmid (Clontech, Mountain View, CA, U.S.A.) in place of the *eGFP* gene. This new plasmid allowed for constitutive expression of iRFP directed by the CMV promoter.

The iRFP plasmid was transformed into *Escherichia coli* bacterial strain TOP10 and pure, supercoiled plasmid for transfection was isolated with the EndoFree Plasmid Maxi kit (\#12363, Qiagen, Hilden, Germany) using manufacturer's instructions. The identity of the plasmid preparation was confirmed by DNA sequencing followed by measurement of the purity and concentration through the 260/280 nm ratio of UV absorbance using a NanoDrop spectrophotometer (Thermo Scientific, Wilmington, DE, U.S.A.).

Synthesis of cross-linked low molecular weight PEI (CLPEI) for *in vivo* studies {#S12}
--------------------------------------------------------------------------------

CLPEI was synthesized as previously reported ^[@R14]^. Briefly, LPEI (160 μmol) dissolved in distilled water was mixed with dithiobis(succinimidyl propionate) (142 μmol) in dimethyl sulfoxide and reacted at 50 °C overnight. The reaction product was purified by dialysis (molecular weight cutoff: 1000 Da), converted to a chloride salt form, and lyophilized.

Preparation of pDNA complexes for *in vivo* delivery {#S13}
----------------------------------------------------

Experimental ternary complexes (pDNA/3E/DS, pDNA/CLPEI/DS, pDNA/3E/HA, and pDNA/CLPEI/HA) were prepared as described above, typically in a ratio of 3.3/1/0.1. For one experiment examining the optimal concentration of pDNA for in vivo delivery, ratios of 1.6/1/0.1, 6.6/1/0.1, and 16.5/1/0.1 were used.

*In vivo-*jetPEI nucleic acid delivery reagent (Polyplus-transfection, Illkirch, France), Entranster-*in vivo* transfection reagent (EnGreen Biosystem Ltd., Beijing City, China), and Coatsome EL-01-D liposomes (NOF Corporation, New York, NY, U.S.A.) were each prepared per their manufacturer's instructions in order to deliver 20 μg pDNA per 100 μL injection. Three days following tumor irradiation, pDNA-carrier complexes were prepared and systemically delivered by retro-orbital injection. For evaluation of statistical significance between carriers, pDNA complexes were compared to the best performing commercial PEI vector, EnTranster.

Mice {#S14}
----

Six-week-old BALB/c female mice were purchased from Harlan Laboratories (Madison, WI, U.S.A.). 1 × 10^6^ *in vitro* cultured TUBO tumor cells were injected subcutaneously into the hindlimb of mice to induce tumor growth. Tumor size was measured biweekly using calipers with tumor volume calculated using the formula V = l × w × (h/2). Ternary polyplexes (equivalent to 10--100 μg iRFP pDNA per animal) were administered via retro-orbital injection in a volume of 100 μL. All animal studies were performed in compliance and with the approval of the University of Chicago Institutional Animal Care and Use Committee, ACUP\# 72354.

Irradiation {#S15}
-----------

Tumors were irradiated once they reached 200--300 mm^3^ in volume. An X-RAD 225Cx small animal irradiator (Precision X-Ray Inc., N. Bradford, CT, U.S.A.) was used to plan and deliver X-ray ionizing radiation in a two-step process involving computed tomography ^[@R32]^ imaging followed by image-guided delivery of a precise treatment dose. The X-ray source was used for both imaging (1.0 mm focal spot) and treatment (5.5 mm focal spot). The subject was immobilized using isoflurane anesthesia and secured on the irradiator stage using surgical tape. Treatment planning began using the X-RAD 225C software and involved two sequential CT images taken through a 2.0 mm Al filter including an initial scout (40 kVp, 0.5 mA, 0.3 mm isotropic voxels), followed by a more detailed full scan (40 kVp, 2.5 mA, 0.1 mm isotropic voxels). DICOM files of the detailed CT scan were exported into a treatment planning application written in MATLAB (The MathWorks Inc., Natick, MA, USA) for selection of the treatment isocenter, planning of an irradiation protocol, and evaluation of the selected treatment fields. In the present experiments, irradiation protocols were designed with fields from two opposing directions, each delivering half the desired total dose. The software also calculated the 3D shift of the animal support stage required to position the chosen target at the radiation isocenter for treatment. Radiotherapy was performed following import of the treatment protocol into the XRAD 225C software, which automated delivery of the planned fields. Treatments were performed at 225 kVp, 13 mA and 0.3 mm Cu filter, with a 1.5 cm diameter lead collimator providing a dose rate of \~2.5 Gy/min. The irradiator output was calibrated according to the American Association of Physicists in Medicine Task Group 61 ^[@R33]^ protocol using a Farmer type chamber. Doses of 5 and 15 Gy were used in this study with total treatment time lasting up to 15 min, including set-up.

Fluorescence imaging of biodistribution {#S16}
---------------------------------------

To examine fluorescence in tissues *ex vivo*, the Xenogen IVIS 200 (Caliper Life Sciences, Hopkinton, MA, USA) was used at the 4 hrs, 1 d, 2 d, 3 d and 7 d time points after pDNA injection to quantitatively measure fluorescent probe permeation and retention in differentially treated tumors. Dissected tumors, as well as other tissues such as liver, spleen, heart, kidney, and lung, were imaged for pDNA fluorescence from iRFP expression from pDNA. The radiant efficiency, a relative measure of photon emission from the tissue (photons/sec/cm^2^/sr/(μW/cm^2^)), was measured with variables such as exposure time, binning, and f/stop standardized. Intestinal pDNA retention of iRFP-expressing pDNA was unable to be examined due to autofluorescence from ingested chow ^[@R34]^.

Statistical analysis {#S17}
--------------------

Data are expressed as the mean ± SEM unless specified otherwise. Statistical analyses were carried out using Prism (GraphPad Software, Inc., La Jolla, CA, USA). Prior to analyses, data to be tested were confirmed to be of a normal distribution and F-tests were performed to compare variances between groups. In most instances, two-sided unpaired Student's t test was used to determine significance between an experimental group and a control group with a value of p ≤ 0.05 considered significant. For comparisons across multiple groups, two-way ANOVA followed by Sidak's multiple comparisons test was used.

Results {#S18}
=======

Modification of the common cationic polymer LPEI with LCA strengthens complex assembly with pDNA {#S19}
------------------------------------------------------------------------------------------------

To synthesize a DNA delivery conjugate consisting of low molecular weight (2.5 kDa) linear PEI modified with LCA, carbodiimide chemistry was utilized. The two compounds were dissolved in dichloromethane, then combined in a mixture with dicyclohexyl carbodiimide and N,N-diisopropyl-ethylamine and reacted over 15 hours. Synthesis of the resulting conjugate, 3 molar equivalents LCA to 1 mole LPEI or "3E", was confirmed by H-NMR assessment of the additional proton shifts indicating the steroid framework in 0.6 -- 1.8 ppm ([Fig. 1a](#F1){ref-type="fig"}).

3E formed binary polyplexes with plasmid DNA (pDNA) with a diameter of 455.4 ± 19.7 nm and 214.6 ± 6.3 nm at the pDNA/3E ratios of 1/10 and 1/20, respectively ([Table 1](#T1){ref-type="table"}). The toxicity of 3E was tested using both the NIH3T3 (mouse embryonic fibroblasts) and MCF7 (human mammary adenocarcinoma) cell lines. Relative to unmodified LPEI, 3E showed a slightly higher dose-dependent toxicity ([Fig. 1b](#F1){ref-type="fig"}). LCA conjugation seemed responsible for the additional toxicity. Accordingly, the reporter gene *in vitro* transfection in the following section was carried out at a concentration at which 3E was not apparently toxic (2 μg/mL).

A gel migration assay was performed to examine electrostatic interactions between the cationic polymers and pDNA and also to determine the optimal polymer to DNA weight ratio for assembly of a neutral complex. Both LPEI and 3E formed complexes with pDNA (pEGFP-C1, 4.7 kb) at a polymer/pDNA weight ratio of 1/1 or higher ([Fig. 1c](#F1){ref-type="fig"}). At the polymer/pDNA ratio of 0.3/1, LPEI/pDNA binary complex showed partial retardation, whereas 3E/pDNA was almost completely retarded ([Fig. 1c](#F1){ref-type="fig"}). This indicates that 3E formed a complex with pDNA more readily than the parent LPEI, suggesting that hydrophobic interactions between LCA moieties provided additional driving force for DNA complex assembly.

Addition of dermatan sulfate to the pDNA/3E complex increases its stability as a nucleic acid carrier and transfection efficiency {#S20}
---------------------------------------------------------------------------------------------------------------------------------

To test the feasibility of systemic application, ternary polyplexes were formed combining 3E, dermatan sulfate (DS) and plasmid DNA, yielding particles with sizes of 757.9 ± 31.9 nm (pDNA/3E/DS = 1/10/1) and 325.9 ± 13.1 nm (pDNA/3E/DS=1/20/1) ([Table 1](#T1){ref-type="table"}). DS was chosen for its ability to mask the cationic surface charges of the DNA delivery complexes without compromising their ability to interact with tumor cells. pDNA/3E/DS ternary polyplexes were challenged with DNase and heparin to model interactions with endogenous nucleases and negatively charged macromolecules present in blood, respectively. Stability of the 3E polyplex was compared with a polyplex containing the parent LPEI, pDNA/LPEI/DS. DNase degraded free pDNA, whereas pDNA in both ternary polyplexes was protected ([Fig. 1d](#F1){ref-type="fig"}). Heparin acts as a competitor anionic molecule leading to the release of DNA from complexes based on the strength of interaction. Heparin managed to uncouple the pDNA/LPEI/DS polyplexes, yielding bands of free pDNA after 2 hrs of incubation. On the other hand, pDNA/3E/DS polyplexes were noticeably more stable in the presence of heparin. Dual treatment with DNase and heparin showed a similar pattern with complete degradation of free pDNA and the disassembly of pDNA/LPEI/DS polyplex. pDNA/3E/DS polyplex was least affected by heparin/DNase dual treatment. This result demonstrates the improved stability of 3E-containing polyplex due to LCA conjugation.

To examine *in vitro* transfection efficiency, the polyplexes were prepared at varying polymer/pDNA weight ratios (10/1 to 20/1 w/w). A plasmid encoding enhanced green fluorescent protein (EGFP) in transfected cells was used as a reporter gene. The addition of DS to the complexes increased the reporter gene transfection for both LPEI and 3E polyplexes at all levels of polymer/pDNA ratios in NIH3T3 and MCF7 cells ([Fig. 2a,b](#F2){ref-type="fig"}).

Increased tumor delivery and specificity of modified PEI carriers compared to commercial gene delivery vectors {#S21}
--------------------------------------------------------------------------------------------------------------

To examine the *in vivo* efficiency of the pDNA/modified PEI complexes, TUBO tumors were grown in BALB/c mice as a model for cancer gene therapy. In order to track DNA delivery and transfected protein expression, a plasmid constitutively expressing a near infrared fluorescent protein, iRFP, was constructed and used as a proxy for gene therapy. The far-red excitation and near-infrared emission of iRFP facilitated *in vivo* fluorescent imaging using a Xenogen IVIS fluorescence imaging system to detect tumor as well as normal tissue transfection. A disulfide-crosslinked version of LPEI (CLPEI) was used instead of LPEI for *in vivo* evaluation based upon previous studies that found disulfide-crosslinked PEI to be superior to LPEI in pharmacokinetics and *in vivo* gene transfection ^[@R35]^. Therefore, transfection mediated by the pDNA/3E/DS complex was compared to pDNA/CLPEI/DS, as well as commercial PEI and liposomal nucleic acid carriers ([Supp. Fig. 1a--i](#SD1){ref-type="supplementary-material"}). The commercial liposomes (Coatsomes) hold a slightly cationic charge and consist of dioleoylphosphatidylethanolamine (DOPE), cholesterol, and O,O′-ditetradecanoyl-N-(α-trimethylammonioacetyl) diethanolamine chloride in a 0.75/0.75/1 ratio. Additionally, ternary complexes were prepared with hyaluronic acid (HA) instead of DS as HA has also been commonly used for polycation neutralization to date ^[@R36]^.

Quantification of iRFP fluorescence 4 hrs after retro-orbital administration revealed that enhanced tumor accumulation of pDNA occurred using polyplexes containing 3E and CLPEI, with the greatest delivery seen in combination with DS ([Fig. 3a](#F3){ref-type="fig"}, [Supp. Fig. 1a,b](#SD1){ref-type="supplementary-material"}). Relative to the better performing commercial PEI vector (EnTranster), pDNA/3E/DS and pDNA/CLPEI/DS displayed 518% and 502% of the tumor delivery, respectively. In comparison to the Coatsome liposomal vehicle, pDNA/3E/DS and pDNA/CLPEI/DS exhibited 196% and 190% of the tumor accumulation, respectively. Normal tissues known to take up DNA from prior studies were compared to the tumor from each animal *ex vivo* to evaluate their relative iRFP accumulation. pDNA/3E/DS and pDNA/CLPEI/DS displayed significantly less signal in the liver than either of the commercial PEI vectors, though commercial liposomes showed the least liver accumulation ([Fig. 3b](#F3){ref-type="fig"}). Accumulation in the spleen ([Fig. 3c](#F3){ref-type="fig"}), kidneys ([Fig. 3d](#F3){ref-type="fig"}), and lungs ([Fig. 3e](#F3){ref-type="fig"}) trended lower in the 3E and CLPEI conjugates compared to their commercial PEI counterparts. The commercial liposomal carrier again showed the least off-target tissue buildup, though not significantly less than that seen in the 3E and CLPEI carriers ([Fig. 3c--e](#F3){ref-type="fig"}).

Tumor irradiation enhances tumor transfection by circulating gene carriers {#S22}
--------------------------------------------------------------------------

Our prior work established enhanced delivery of circulating macromolecules and nanoparticles to irradiated tumors, leading to increased therapeutic effects. Thus, we sought to extend this approach to nanoparticles carrying pDNA. TUBO tumors were grown in the hindlimbs of BALB/c mice and treated with CT-guided irradiation to deliver 5 Gy or 15 Gy. After three days, we injected iRFP loaded in a range of DNA carriers and examined transfection by imaging fluorescence after 4 h. Radiotherapy had the greatest fold effects on delivery of the pDNA/3E/DS (161% after 15 Gy relative to 0 Gy control) and pDNA/CLPEI/DS (252% after 15 Gy relative to 0 Gy) ternary polyplexes ([Fig. 3a](#F3){ref-type="fig"}). The commercial carriers also showed a trend towards increased tumor accumulation of iRFP plasmid following IR, though only EnTranster after 15 Gy displayed a significant increase (385% relative to 0 Gy). Increased tumor accumulation following irradiation was associated with decreased off-target delivery to liver or spleen ([Fig. 3b,c](#F3){ref-type="fig"}). While the liposomal Coatsome carrier displayed less accumulation in these tissues compared to pDNA/CLPEI/DS and pDNA/3E/DS in unirradiated controls, this disparity was decreased after irradiation. Irradiation did not display a consistent effect on off-target delivery to kidney or lung ([Fig. 3d,e](#F3){ref-type="fig"}).

Toward obtaining optimal radiation-enhanced transfection by iRFP plasmid, we examined a range of ratios of DNA to PEI in the pDNA/CLPEI/DS complex. A 3.3/1 ratio of DNA to CLPEI complex appeared to provide the highest delivery, albeit with or without irradiation ([Fig. 4a](#F4){ref-type="fig"}). As the DS containing PEI carriers displayed a promising combination of increased tumor delivery and decreased off-target tissue accumulation, we chose to examine these two DNA vehicles over time. Neither pDNA/3E/DS nor pDNA/CLPEI/DS showed a significant decrease in signal in the tumor from 4 h to 1 wk after administration with IR appearing to enhance tumor delivery and accumulation of both vehicles ([Fig. 4b](#F4){ref-type="fig"}). In general, it would appear that using pDNA/3E/DS leads to less off-target plasmid accumulation in the liver, spleen, and kidneys relative to pDNA/CLPEI/DS ([Supp. Fig 2a--c](#SD1){ref-type="supplementary-material"}). Off-target delivery to the lung was not significant under any conditions with these carriers ([Supp. Fig. 2d](#SD1){ref-type="supplementary-material"}).

Discussion {#S23}
==========

While polycation DNA carriers such as polyethyleneimine (PEI) are satisfactory for *in vitro* transfection, their performance *in vivo* as non-viral gene therapy vectors has been less than optimal. Nonspecific uptake by the reticuloendothelial system, dissociation of the DNA from the carrier and destruction of the DNA by nucleases limit the value of PEI *in vivo*. Fortunately, a beneficial feature of PEI is that modifications can easily be made to its basic structure and composition to address these challenges. By conjugating lithocholic acid (LCA) to low molecular weight linear PEI (LPEI, 2.5 kDa) and complexing with dermatan sulfate (DS), we found that stability and transfection efficiency of the ternary polyplex pDNA/3E/DS was enhanced without appreciably affecting cytotoxicity *in vitro*. Furthermore, we used these ternary polyplexes to show that the radiation-enhanced permeability and retention that had been applied to delivery of macromolecules and nanoparticles to tumors ^[@R30]^ can also facilitate *in vivo* transfection with plasmid DNA.

Conjugation of LCA to PEI conferred greater stability to the complexes with pDNA *in vitro* and enhanced transfection *in vivo*. The latter effect may be mediated by improved stability in circulation but also enhanced cell uptake. Lipid modification of PEI is known to facilitate cellular uptake, presumably through enhancing polyplex interactions with intracellular membranes ^[@R37]^. While previous attempts to use lipids conjugated to PEI similarly enhanced nucleic acid delivery ^[@R21],\ [@R38]^, LCA-modified PEI polyplexes suffered from aggregation due to hydrophobic interactions between LCA moieties ^[@R38]^. Neither binary nor ternary complexes containing 3E showed micro-sized aggregates at the pDNA/3E/(DS) ratio of 1/10/(1) or 1/20/(1). Ternary complexes with a high content of pDNA prepared for *in vivo* studies showed an average size in the micrometer range ([Table 1](#T1){ref-type="table"}), but these aggregates were temporary and mostly resolved in serum (data not shown); thus, we infer that the addition of DS helped maintain dispersity. *In vivo*, masking the polycation surface charge with DS has been shown to decrease toxicity and unwanted sequestration by cells of the reticuloendothelial system, thus increasing transfection efficiency ^[@R16],\ [@R39]^. Generating ternary polyplexes using DS led to not only increased accumulation of pDNA in the target tissue, but also prolonged retention allowing for cellular uptake and expression. Moreover, DS-complexed polyplexes displayed less off-target tissue expression than their commercial PEI counterparts.

As transfection efficiency increases for a cancer gene-therapy vector, so does the need for targeted delivery to tumors. Inappropriate delivery of the cargo and gene expression in peripheral tissue could have significant adverse consequences. We observed that following image-guided tumor irradiation, each of the non-viral gene delivery vectors tested displayed increased tumor accumulation. The most favorable results were obtained with the pDNA/3E/DS and pDNA/CLPEI/DS polyplexes where radiation increased tumor delivery and decreased accumulation in the liver. Taken together, our data support further development of PEI based carriers and suggest that further development of radiation-enhanced delivery and retention is warranted as a strategy to improve the therapeutic ratio of cancer gene therapy, independent of carrier.
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![The 3E complex of low molecular weight linear polyethyleneimine (LPEI) conjugated to lithocholic acid (LCA) and complexed with dermatan sulfate (DS) forms a stable polyplex with pDNA. a) Synthetic schematic and H-NMR analysis of 3E formation. Blue letters correspond to chemical shifts shown in NMR chart (right). b) Cytotoxicity of 3E not substantially increased relative to LPEI in NIH3T3 and MCF7 cell lines. Arrows indicate the concentration at which *in vitro* transfection efficiency was tested. n = 6 for each group; error bars = S.D. c) Gel retardation assay reveals 3E readily complexes with pDNA. 0.2 μg pDNA per lane. d) Degradation of pDNA by DNase and/or heparin is retarded after encapsulation with 3E ternary polyplex (pDNA/polymer/DS = 1/15/1).](nihms902013f1){#F1}

![Transfection efficiency of 3E and LPEI polyplexes is increased by conjugation to DS. a) EGFP expressing pDNA transfected into NIH3T3 cells and visualized by fluorescence microscopy. b) Quantification of transfected GFP expression in NIH3T3 and MCF7 cells through measuring of the fluorescence intensity of the supernatant of the cell lysate. 10/1 to 20/1 polymer/pDNA weight ratios examined ± DS. n = 9 for each group; error bars = S.D.; \* indicates p ≤ 0.05; \*\* indicates p ≤ 0.001.](nihms902013f2){#F2}

![3E/DS and CLPEI/DS polyplexes provide high tumor delivery that is enhanced by tumor irradiation. a) IVIS quantification of tumor iRFP fluorescence 4 hrs following intravenous administration of 3E, CLPEI, and commercial pDNA vectors. Tumor irradiation was performed 3 days prior to injection of pDNA vector. n ≥ 4 for each vector; error bars = SEM. b--e) IVIS quantification of off-target liver (b), spleen (c), kidney (d), and lung (e) iRFP fluorescence relative to tumor iRFP fluorescence in the same animal. Horizontal dotted line indicates relative tumor fluorescence. n = 3 for each vector; error bars = SEM; \* indicates p ≤ 0.05 relative to EnTranster of same IR dose; \# indicates p ≤ 0.05 relative to 0 Gy of same pDNA carrier.](nihms902013f3){#F3}

![Radiation-enhanced delivery of DS-conjugated polyplexes leads to durable gene expression in tumors. a) IVIS quantification of iRFP fluorescence 72 hrs after delivery of varying amounts of pDNA complexed with CLPEI/DS. Key denotes ratios of pDNA/CLPEI/DS; n ≥ 4 for each ratio; error bars = SEM; \# indicates p ≤ 0.05 relative to 0 Gy of same pDNA/CLPEI ratio. b) IVIS quantification of iRFP fluorescence from 4 h to 1 wk after administration of 20 μg iRFP pDNA. n ≥ 4 for each time point; error bars = SEM; \# indicates p ≤ 0.05 relative to 0 Gy of same pDNA carrier and time point.](nihms902013f4){#F4}

###### 

Particle size and zeta potential of binary and ternary complexes

  Complex                     pDNA       Polymer       Polysaccharide   z-average (d, nm)   Zeta potential (mV)
  --------------------------- ---------- ------------- ---------------- ------------------- ---------------------
  pDNA/LPEI (1/10)            pLuc (1)   LPEI (10)     \-\--            2263.1±148.5        11.8±1.1
  pDNA/LPEI (1/20)            pLuc (1)   LPEI (20)     \-\--            700.6±11.5          12.5±1.0
  pDNA/CLPEI (1/10)           pLuc (1)   CLPEI (10)    \-\--            178.5±2.8           10.2±1.3
  pDNA/CLPEI (1/20)           pLuc (1)   CLPEI (20)    \-\--            118.4±2.3           8.5±0.1
  pDNA/3E (1/10)              pLuc (1)   3E (10)       \-\--            455.4±19.7          14.7±0.1
  pDNA/3E (1/20)              pLuc (1)   3E (20)       \-\--            214.6±6.3           12.9±0.9
  pDNA/LPEI/DS (1/10/1)       pLuc (1)   LPEI (10)     DS (1)           318.3±5.4           8.8±4.0
  pDNA/LPEI/DS (1/20/1)       pLuc (1)   LPEI (20)     DS (1)           174.4±14.4          12.7±.4
  pDNA/CLPEI/DS (1/10/1)      pLuc (1)   CLPEI (10)    DS (1)           318.3±5.4           14.8±0.2
  pDNA/CLPEI/DS (1/20/1)      pLuc (1)   CLPEI (20)    DS (1)           174.4±14.4          12.7±0.9
  pDNA/3E/DS (1/10/1)         pLuc (1)   3E (10)       DS (1)           757.9±31.9          14.3±0.8
  pDNA/3E/DS (1/20/1)         pLuc (1)   3E (20)       DS (1)           325.9±13.1          15.2±0.5
  pDNA/CLPEI/DS (3.3/1/0.1)   pLuc (1)   CLPEI (0.3)   DS (0.03)        688.6±124.1         −32.3±1.1
  pDNA/CLPEI/HA (3.3/1/0.1)   pLuc (1)   CLPEI (0.3)   HA (0.03)        1059.1±48.8         −33.4±1.1
  pDNA/3E/DS (3.3/1/0.1)      pLuc (1)   3E (0.3)      DS (0.03)        3315.8±505.6        −23.4±1.6
  pDNA/3E/HA (3.3/1/0.1)      pLuc (1)   3E (0.3)      HA (0.03)        4061.1±385.5        −18.6±3.0

Average ± standard deviation of 3 identically and independently prepared samples.
